CY1107858T1 - Ccr5 αντισωματα pa14 - Google Patents

Ccr5 αντισωματα pa14

Info

Publication number
CY1107858T1
CY1107858T1 CY20081100062T CY081100062T CY1107858T1 CY 1107858 T1 CY1107858 T1 CY 1107858T1 CY 20081100062 T CY20081100062 T CY 20081100062T CY 081100062 T CY081100062 T CY 081100062T CY 1107858 T1 CY1107858 T1 CY 1107858T1
Authority
CY
Cyprus
Prior art keywords
monoclonal antibody
ccr5
binds
fragment
options
Prior art date
Application number
CY20081100062T
Other languages
English (en)
Inventor
William C Olson
Paul J Maddon
Original Assignee
Progenics Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals, Inc. filed Critical Progenics Pharmaceuticals, Inc.
Publication of CY1107858T1 publication Critical patent/CY1107858T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Αυτή η εφεύρεση παρέχει μία σύνθεση για την καταστολή της μόλυνσης από HIV-1 που περιλαμβάνει τουλάχιστον δύο ενώσεις σε συνεργατικά αποτελεσματικές ποσότητες για την καταστολή της μόλυνσης από HIV-1, όπου τουλάχιστον μία από τις ενώσεις εμποδίζει την παραγωγική αλληλεπίδραση μεταξύ του HIV-1 και ενός συνλήπτη συγχώνευσης HIV-1. Αυτή η εφεύρεση παρέχει επίσης μία σύνθεση που αναστέλλει την συγχώνευση του HIV-1 ή ενός κυττάρου γλυκό-πρωτεΐνης+ του περιβλήματος του HIV-1 με ένα κύτταρο στόχου, όπου τουλάχιστον μία από τις ενώσεις εμποδίζει την παραγωγική αλληλεπίδραση μεταξύ του HIV-και ενός συνλήπτη συγχώνευσης HIV-1. Αυτή η εφεύρεση παρέχει επίσης μία μέθοδο θεραπείας ενός ατόμου που έχει προσβληθεί από HIV-1 που περιλαμβάνει την χορήγηση στο άτομο μιας αποτελεσματικής δόσης των εν λόγω συνθέσεων. Αυτή η εφεύρεση παρέχει επίσης μία μέθοδο προφύλαξης ενός ατόμου από την προσβολή από HIV-1 που περιλαμβάνει την χορήγηση στο άτομο μιας αποτελεσματικής δόσης των εν λόγω συνθέσεων. Αυτή η εφεύρεση παρέχει επίσης ένα μονόκλωνο αντίσωμα anti-CCR5 που επιλέγεται από την ομάδα που αποτελείται από PA8, ΡΑ9, PA10, PAΗ, PA12, και ΡA14.
CY20081100062T 1998-12-16 2008-01-17 Ccr5 αντισωματα pa14 CY1107858T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21279398A 1998-12-16 1998-12-16
US11253298P 1998-12-16 1998-12-16
EP99966466A EP1144006B1 (en) 1998-12-16 1999-12-16 CCR5 Antibody PA14

Publications (1)

Publication Number Publication Date
CY1107858T1 true CY1107858T1 (el) 2013-06-19

Family

ID=26810060

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100062T CY1107858T1 (el) 1998-12-16 2008-01-17 Ccr5 αντισωματα pa14

Country Status (13)

Country Link
EP (2) EP1144006B1 (el)
JP (1) JP2002538771A (el)
AT (1) ATE375802T1 (el)
AU (3) AU773175B2 (el)
CA (1) CA2355607A1 (el)
CY (1) CY1107858T1 (el)
DE (1) DE69937369T2 (el)
DK (1) DK1144006T3 (el)
ES (1) ES2296416T3 (el)
HK (1) HK1041207B (el)
MX (1) MXPA01006097A (el)
PT (1) PT1144006E (el)
WO (1) WO2000035409A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261763B1 (en) 1995-06-07 2001-07-17 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US20020146415A1 (en) * 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
ATE291035T1 (de) * 2001-12-21 2005-04-15 Micromet Ag Einzelne und duale anti-cd4-rantes chemokin/zytokin konstrukte
DK1478738T3 (da) * 2002-02-22 2009-03-09 Pdl Biopharma Inc Anti-CCR5-antistof
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP2009525301A (ja) * 2006-01-30 2009-07-09 エフ．ホフマン−ラ ロシュ アーゲー Ｈｉｖを処置するための相乗的組成物
MX2009001204A (es) 2006-08-17 2009-02-11 Hoffmann La Roche Conjugado de un anticuerpo cointra ccr5 y un peptido antifusogenico.
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
KR20090052358A (ko) 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
CL2008000707A1 (es) 2007-03-13 2008-09-22 Hoffmann La Roche Conjugado de polipeptidos antifusogenicos y polipeptidos derivados de la cabeza globular del factor del complemento c1q; composicion farmaceutica que lo comprende; su uso para tratar infecciones viricas; y metodo de produccion.
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0975749A2 (en) * 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antibodies thereto, transgenic animals
CA2257991A1 (en) * 1996-06-14 1997-12-18 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting hiv-1 infection
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same

Also Published As

Publication number Publication date
CA2355607A1 (en) 2000-06-22
PT1144006E (pt) 2007-12-11
HK1041207B (zh) 2007-12-28
EP2088158A2 (en) 2009-08-12
DK1144006T3 (da) 2007-11-26
DE69937369D1 (de) 2007-11-29
EP1144006A2 (en) 2001-10-17
ES2296416T3 (es) 2008-04-16
AU2199600A (en) 2000-07-03
MXPA01006097A (es) 2002-04-15
DE69937369T2 (de) 2008-07-24
AU2004205164A1 (en) 2004-09-16
EP2088158A3 (en) 2010-01-20
HK1041207A1 (en) 2002-07-05
WO2000035409A2 (en) 2000-06-22
WO2000035409A3 (en) 2000-09-14
JP2002538771A (ja) 2002-11-19
EP1144006A4 (en) 2004-11-24
ATE375802T1 (de) 2007-11-15
EP1144006B1 (en) 2007-10-17
AU2004205165A1 (en) 2004-09-16
AU773175B2 (en) 2004-05-20

Similar Documents

Publication Publication Date Title
CY1107858T1 (el) Ccr5 αντισωματα pa14
NZ616992A (en) Anti-ilt7 antibody
DE69429095D1 (de) Humanisierte antikoerper
IL226637A0 (en) An isolated heterodimeric cytokine receptor
ATE324381T1 (de) Mutiertes scfv-fragment des okt-3 antikörpers
CA2221893A1 (fr) Anticorps specifique de staphylococcus aureus et utilisations
NZ621483A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
RS20130234A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
HK1115607A1 (en) Human cytokine receptor
RU2005132389A (ru) Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
RU96107203A (ru) Моноклональные антитела, обладающие способностью вызывать апоптоз
DE60014124D1 (de) Antikörper, die spezifisch für fullerene sind
EP0257778A3 (en) Apolipoprotein b-specific monoclonal antibodies produced by two novel hybridomas
MX9702422A (es) Anticuerpos recombinantes contra fas y adn para los mismos.
DE3580382D1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
ES2114547T3 (es) Anticuerpos monoclonales contra el virus de la hepatitis c.
ATE229080T1 (de) Monoklonale antikörper gegen ck-mb
EP0265156A3 (en) Monoclonal antibodies
EP0349258A3 (en) Method of determining the differentiation of a human t-cell
SE9501302D0 (sv) Antibodies for use in cancertherapy and diagnosis
KR960023044A (ko) 재조합 인간 에리스로포이에틴에 대한 단일클론항체 및 이를 생산하는 신규의 융합세포주
EP1734054A3 (en) Anti-human thymidylate synthase monoclonal antibody and hybridoma capable of producing the same